Therapeutic efficacy of compound C-283 in patients with mammary carcinoma.
D000166:Acridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents; D001943:Breast Neoplasms / Q000188:drug therapy*; D004123:Dimethylamines / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D004912:Erythrocytes; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007677:Kidney Function Tests; D007962:Leukocytes; D008111:Liver Function Tests; D009574:Nitro Compounds / Q000009:adverse effects / Q000627:therapeutic use; D010689:Phlebitis / Q000139:chemically induced; D012075:Remission, Spontaneous; D014556:Urine / Q000166:cytology; D014839:Vomiting / Q000139:chemically induced
D000166:Acridines; D000970:Antineoplastic Agents; D004123:Dimethylamines; D009574:Nitro Compounds